Clinical Trials

  • Principal Investigator:

    Uma M. Reddy, MD, MPH
    This study will enroll participants who did or did not receive a SARS-CoV-2 vaccine during their pregnancy and have a child who is now 18-30 months of age. In order to assess the long-term outcomes of the offspring of those who received SARS-CoV-2 vaccine in pregnancy, a cohort study examining child developmental outcomes is needed. There are a number of known tests of developmental milestones that are easy to administer and can be administered remotely.
  • Principal Investigator:

    June Y. Hou, MD
    This research study has two parts. Participants will be enrolled in the second part of the study. The names of the study drugs are RGX-104, nivolumab, ipilimumab, docetaxel, carboplatin, and pemetrexed. The purpose of the first part of the study is to determine the highest dose of RGX-104 the body can handle. The purpose of the second part is to determine if the highest dose of RGX-104 determined in the first part might be an effective treatment option for people with advanced cancers. Both parts of the study will try to understand the safety and side effects of RGX-104.
  • Principal Investigator:

    S. Zev Williams, MD, PhD
    Researchers at Columbia are looking at new treatments to help delay the start of menopause. This is a randomized trial where some women will receive medication and some will receive a placebo. The study will last approximately 12 weeks, followed by monthly follow-ups for 6 months. Participants will be compensated $1300 for compensation.
  • Principal Investigator:

    June Y. Hou, MD
    The main purpose of this study is to: Learn about the safety of REGN4018 and to find out what dose of REGN4018 can be given alone or in combination with cemiplimab to research subjects with ovarian cancer without too many side effects. The study will also look at the levels of REGN4018 and/or cemiplimab in the body and measure how well your body can remove the study drug(s). This is called pharmacokinetics. The study will also look at any signs that REGN4018 alone or with cemiplimab can treat cancer.
  • Principal Investigator:

    June Y. Hou, MD
    The purpose of this research study is to test the safety and determine the highest tolerable dose of SL-172154 (study drug) that can be given with Pegylated Liposomal Doxorubicin (PLD) or Mirvetuximab Soravtansine (MIRV). Another purpose of this study is to understand if SL-127154 and PLD or MIRV is effective in managing ovarian cancer. The study drug, SL-172154 is an immunotherapy drug. Immunotherapies are treatments that use your bodys own immune (defense) system to help fight cancer. SL-172154 binds to a protein called CD47 on cancer cells and to a protein called CD40 on immune cells...
  • Principal Investigator:

    June Y. Hou, MD
    The purpose of this research is to learn about what effects, both good and/or bad, an experimental drug called TransCon IL-2 / has when given by itself SOC chemotherapy, or experimental drug called TransCon TLR7/8 Agonist, or in combination with SOC chemotherapy. TransCon IL-2 / works by blocking the reproduction and spread of cancer cells. The study drugs TransCon IL-2 / and TransCon TLR7/8 Agonist (TLR7/8) have not been approved by the Food and Drug Administration FDA for your type of cancer. We also want to find a dose of TransCon IL-2 / that is safe and tolerable for adult patients who...
  • Principal Investigator:

    June Y. Hou, MD
    Participants are being invited to take part in a clinical research study because they have been diagnosed with locally advanced or metastatic solid tumors with mutations in the following genes: MRE11, RAD50, NBN, or CCNE1 amplification. If the participant takes part in the study, they will take an investigational drug referred to as ZN-c3 (Study Drug). Investigational means that the Study Drug is currently being tested and has not been approved by the U.S. Food and Drug Administration (FDA) or any other health or regulatory authority in other countries. The purpose of this study includes the...
  • Principal Investigator:

    Paula M Castaño, MD, MPH
    The study is looking to evaluate levonogestrel butanoate as a possible new long-acting injectable for birth control. Levonogestrel butanoate is a type of hormone called progestin that has a long history of clinical use in a variety of birth control methods (e.g. pills, intrauterine devices, implants) and its efficacy and safety are well recognized. This study is seeking for healthy female volunteers between the ages of 18-40 years of age. Participation time is estimated to last up to 9 months with approximately 36 study visits. The first visit will last about 1 hour and all other visits will...

Pages